| Dr Daniel Sanders, MD | |
|
1120 Raintree Cir Ste 110, Allen, TX 75013-5257 | |
| (817) 442-9300 | |
| Not Available |
| Full Name | Dr Daniel Sanders |
|---|---|
| Gender | Male |
| Speciality | Pain Management |
| Experience | 10 Years |
| Location | 1120 Raintree Cir Ste 110, Allen, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114345956 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LP2900X | Anesthesiology - Pain Medicine | S1503 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Texas Health Presbyterian Hospital Allen | Allen, TX | Hospital |
| Methodist Mckinney Hospital | Mckinney, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Health Back Care | 1951604313 | 43 |
News Archive
Tech Company Curo Consulting have received the highest accolade given to British business. In July, Her Majesty's representative, the Lord Lieutenant of Buckinghamshire, Sir Henry Aubrey-Fletcher visited Curo Consulting's offices in Marlow to present the award in person. The team were also invited to attend a reception at Buckingham palace.
FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.
Survival following heart transplantation is associated with several patient characteristics, including patient education, higher social and economic satisfaction, and patient adherence with medications, according to a study published in the March 2013 issue of The Annals of Thoracic Surgery.
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan.
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.
› Verified 2 days ago
| Entity Name | Texas Health Back Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811366982 PECOS PAC ID: 1951604313 Enrollment ID: O20160120000272 |
News Archive
Tech Company Curo Consulting have received the highest accolade given to British business. In July, Her Majesty's representative, the Lord Lieutenant of Buckinghamshire, Sir Henry Aubrey-Fletcher visited Curo Consulting's offices in Marlow to present the award in person. The team were also invited to attend a reception at Buckingham palace.
FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.
Survival following heart transplantation is associated with several patient characteristics, including patient education, higher social and economic satisfaction, and patient adherence with medications, according to a study published in the March 2013 issue of The Annals of Thoracic Surgery.
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan.
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel Sanders, MD 1340 S Main St Ste 100, Grapevine, TX 76051-5547 Ph: (682) 651-1908 | Dr Daniel Sanders, MD 1120 Raintree Cir Ste 110, Allen, TX 75013-5257 Ph: (817) 442-9300 |
News Archive
Tech Company Curo Consulting have received the highest accolade given to British business. In July, Her Majesty's representative, the Lord Lieutenant of Buckinghamshire, Sir Henry Aubrey-Fletcher visited Curo Consulting's offices in Marlow to present the award in person. The team were also invited to attend a reception at Buckingham palace.
FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.
Survival following heart transplantation is associated with several patient characteristics, including patient education, higher social and economic satisfaction, and patient adherence with medications, according to a study published in the March 2013 issue of The Annals of Thoracic Surgery.
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan.
Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.
› Verified 2 days ago
Dr. Ifeanyi David Nwokeabia, M.D Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N Ste 2110, Allen, TX 75013 Phone: 469-251-8488 | |
Gina Rose Bathurst Nord, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1105 Central Expy N, Suite 375, Allen, TX 75013 Phone: 972-747-5830 Fax: 972-747-5841 | |
Irani S Ekanayake, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 813 Rolling Meadows Ct, Allen, TX 75013 Phone: 214-620-0813 Fax: 972-908-3568 | |
Mr. Wesley Joseph Merritt, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1111 Raintree Cir, Ste. 170, Allen, TX 75013 Phone: 214-509-9691 Fax: 214-509-9661 | |
Mr. Steven Lewis Remer, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1101 Raintree Cir Ste 240, Allen, TX 75013 Phone: 469-326-5100 Fax: 469-326-5101 | |
Dr. Eric Christian Berg, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 906 W Mcdermott Dr, #116-371, Allen, TX 75013 Phone: 972-747-5840 Fax: 972-747-5841 |